Basic Information
TEVETEN TABLET 600 mg
TABLET, FILM COATED
Regulatory Information
SIN11807P
February 21, 2002
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XC09CA02
Company Information
ABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED
ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED
Active Ingredients
Eprosartan (as eprosartan mesylate)
Strength: 600 mg
Detailed Information
Contraindications
**Contra-indications** Known hypersensitivity to components of the product. Pregnancy and lactation. Severe hepatic impairment. The concomitant use of Teveten™ with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73m2) (see Interactions – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**Indication** Treatment of essential hypertension.